A French court ruled that families of children who suffered side effects from the epilepsy medicine Depakine can join in a class-action lawsuit against drugmaker Sanofi.
The company should have warned of the risk of birth defects for pregnant women taking the medicine as early as 1984, a Paris court said Wednesday. Instead it only took those steps in 2003, it said, calling the product that was sold for decades “defective.”
Depakine is a powerful anti-epileptic drug that’s on the World Health Organization’s list of essential medicines, but it has been blamed for neuro-development problems in tens of thousands of children in a long-running court case in Sanofi’s home market. A class-action lawsuit would be a legal first in France, according to Agence France-Presse.
Sanofi said it will appeal the decision. The drugmaker said it has co-operated with authorities and hasn’t been found responsible in any legal proceedings involving Depakine. The stock rose less than 1% in Paris trading.
The class action lawsuit may also be directed at Sanofi’s insurer, a unit of Allianz AG, the court said.
Photograph: Logo on the Sanofi exhibition stand at the Viva Technology conference at Porte de Versailles exhibition center in Paris, France, on Friday, June 18, 2021. Photo credit: Nathan Laine/Bloomberg.
Was this article valuable?
Here are more articles you may enjoy.
Record-Low Danube Water Levels Leave Boats Beached, Reveal Decades-Old Shipwrecks 
Mapfre to Acquire Safety Insurance for $1.54 Billion in Cash Deal 
Jury Awards 78-Year-Old Victim $56 Million for Crash Caused by Amazon Delivery Driver 
Brown & Brown Estimates Cost of Howden-Driven Talent War Could Hit $60M in 2026 
